Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer - PubMed
3 hours ago
- #enzalutamide
- #metastatic castration-resistant prostate cancer
- #radium-223
- The EORTC 1333/PEACE-3 trial evaluated enzalutamide plus radium-223 (Ra223) vs. enzalutamide alone in metastatic castration-resistant prostate cancer (mCRPC).
- Final overall survival (OS) results showed a significant improvement with the combination (HR 0.76, p=0.0096), with median OS of 38.2 months vs. 32.6 months for enzalutamide alone.
- Radiological progression-free survival (rPFS) also improved with the combination (HR 0.71).
- Treatment-emergent grade ≥3 adverse events increased from 57.6% to 69.3% in the combination arm, with hypertension being the most frequent.
- Bone-protecting agents (BPA) were mandatory to reduce skeletal complications.